Karyopharm Therapeutics reported Q2 revenue of $33.43 million, beating estimates thanks to strong sales of its cancer drug XPOVIO®. However, the company missed EPS expectations with a loss of $2.32 per share and faces financial challenges including negative debt-to-equity and cash flow ratios. Karyopharm is shifting focus to its Myelofibrosis program and advancing its Selinexor drug, maintaining its full-year revenue guidance of $130-$150 million.
Grab's Chief Product Officer has sold 30,000 shares, generating $109,200 from the transaction. This insider sale may indicate personal financial planning or a strategic move, but it does not necessarily reflect the company's overall performance. Inve...
Kalshi, a predictive markets platform, saw US visits surge 1,520% to 15.4 million in July 2026, with trading volume hitting $40 billion monthly. Despite ongoing legal challenges over whether its sports contracts fall under federal or state law, Kalsh...
Hyperliquid's AQA v2 model forecasts $193 million in annual revenue and $527,000 daily buybacks of its HYPE token in 2026, signaling strong financial health. This projection has increased market confidence, raising the odds of Hyperliquid reaching $1...
Bitcoin's price has hovered near $80,000 with no clear direction as long-term holders (OGs) increase selling, signaling potential profit-taking. Data shows a spike in Bitcoin moved by holders with assets over five years, indicating some weakening con...
BNB Chain announced it will no longer prioritize reducing gas fees, which it had aggressively cut by over 90% in recent years. Instead, the network aims to develop sustainable business models involving gas fees, revenue sharing, and commercial agreem...
